XOMA 358: Ph II data

Data from 13 patients ages 42-68 with hypoglycemia post-bariatric surgery in an open-label, U.S. Phase II trial showed that single doses of 3, 6 and 9 mg/kg IV XOMA 358 were generally well tolerated. ...